Where is Madrigal Pharmaceuticals EU headquartered?

Madrigal Pharmaceuticals EU Limited is recorded with headquarters in Conshohocken, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Madrigal Pharmaceuticals EU publicly traded?

Yes — Madrigal Pharmaceuticals EU is listed as a public company with ticker MDGL on NYSE in SEC EDGAR-derived records.

What drugs are associated with Madrigal Pharmaceuticals EU?

We link 1 drug profile(s) where Madrigal Pharmaceuticals EU appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Madrigal Pharmaceuticals EU sponsoring?

Madrigal Pharmaceuticals EU is linked to 16 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Madrigal Pharmaceuticals EU as applicant?

26 USPTO PatentsView record(s) name Madrigal Pharmaceuticals EU Limited or a normalized variant as applicant.

What pipeline phases does Madrigal Pharmaceuticals EU have in our database?

Phase distribution from linked programs: phase 1: 7, phase 3: 6, phase 2: 3.

How many US-approved drugs are linked to Madrigal Pharmaceuticals EU?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Madrigal Pharmaceuticals EU hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Madrigal Pharmaceuticals EU?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Madrigal Pharmaceuticals EU data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

pharma · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis (NASH) Cirrhosis · MDGL

Madrigal Pharmaceuticals EU

Name: Madrigal Pharmaceuticals EU intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Madrigal Pharmaceuticals EU Limited

Website Investor relations

200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US HQ

2016 Founded

1,071 Employees

Public company Type

MDGL · NYSE Ticker

Company details

Status: Public
HQ: 200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
Founded: 2016
Employees: 1,071
Programs: 16
Drugs: 11
Patents: 26

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Madrigal Pharmaceuticals EU is a pharma organization headquartered in Conshohocken, USA. It trades on NYSE under ticker MDGL. Primary therapeutic focus areas include Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis (NASH) Cirrhosis, Non-Alcoholic Steatohepatitis (NASH), Renal Impairment, Hepatic Impairment. NovaPharmaNews links 16 clinical program(s), 1 drug profile(s), and 26 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (7), phase 3 (6), phase 2 (3).

Company snapshot

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to hal

2 approved product(s) across US/EU regulatory metadata.
16 active pipeline program(s) linked via ClinicalTrials.gov.
26 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Madrigal Pharmaceuticals EU. Not investment advice.

Top assets

View drugs (11) View projects (16)

Lead pipeline drugs

acetaminophen
approved
alcohol
approved
amlodipine besylate
approved
atorvastatin
Marketed / approved

Active clinical programs

MGL-3196 NASH - Nonalcoholic Steatohepatitis
Phase 3
MGL-3196-11 Non-Alcoholic Steatohepatitis (NASH)
Phase 3
MGL-3196-19 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
Phase 3
Placebo Non-Alcoholic Fatty Liver Disease
Phase 3

Momentum

Proprietary activity score for Madrigal Pharmaceuticals EU.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 17 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Galmed Pharmaceuticals

TA overlap score 32.6
Peer + 0 momentum

ENANTA PHARMACEUTICALS

TA overlap score 26.8
Peer + 0 momentum

Aligos Therapeutics

TA overlap score 22.8
Peer + 0 momentum

Galectin Therapeutics

TA overlap score 22.4

Recent activity

Latest pipeline, patent, and corporate events for Madrigal Pharmaceuticals EU.

Jun 8, 2026 Clinical update
MGL-3196-11 — Phase 3
Jun 8, 2026 Clinical update
MGL-3196-19 — Phase 3
Jun 8, 2026 Clinical update
Simvastatin — Phase 1
Jun 8, 2026 Clinical update
Resmetirom — Phase 3
Jun 8, 2026 Clinical update
MGL-3196 (resmetirom) — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Madrigal Pharmaceuticals EU?

Madrigal Pharmaceuticals EU is a pharma organization headquartered in Conshohocken, USA. It trades on NYSE under ticker MDGL. Primary therapeutic focus areas include Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis (NASH) Cirrhosis, Non-Alcoholic Steatohepatitis (
Is Madrigal Pharmaceuticals EU publicly traded?

Yes. Madrigal Pharmaceuticals EU is listed with ticker MDGL on NYSE per SEC EDGAR records linked on this profile.
What drugs does Madrigal Pharmaceuticals EU develop or market?

We link 11 drug profile(s) where Madrigal Pharmaceuticals EU is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc#company-drugs.
What are the latest developments for Madrigal Pharmaceuticals EU?

In the last 12 months our linked public records show 16 trial program update(s) and 1 US patent grant(s) tied to this profile.
What therapeutic areas does Madrigal Pharmaceuticals EU focus on?

Madrigal Pharmaceuticals EU focuses on Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis (NASH) Cirrhosis, Non-Alcoholic Steatohepatitis (NASH) based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Infectious Disease

Cardiology